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During the past 2 decades, atherosclerosis and its clinical sequelae have increasingly been recognized as an inflammatory
disease. Examination of multiple circulating inflammatory biomarkers has shown that they independently predict
cardiovascular risk in patients with and without overt cardiovascular disease. Among these, high-sensitivity C-reactive
protein has proved to be most robust in adding to global risk prediction models. Statins, a class of drugs that reduce levels
of high-sensitivity C-reactive protein and other inflammatory biomarkers, have been the most thoroughly studied
anti-inflammatory agents to reduce cardiovascular risk. However, all such trials are necessarily confounded by the ability
of statins to markedly reduce cholesterol, a well-known causal risk factor for adverse vascular outcomes. Nevertheless, the
provocative results of several key statin trials have provided the scientific basis to test the hypothesis that reducing
inflammation will improve cardiovascular outcomes with novel and specific anti-inflammatory agents. These newer drugs
promise to reduce inflammatory marker levels without affecting lipids, glucose, or blood pressure. The results of these
trials will provide key data to help us understand the relationship between inflammation and vascular risk. ( J Vasc Surg
2012;56:1799-1806.)
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fiComponents of the innate and adaptive immune sys-
tem have been implicated in a wide variety of vascular
pathologies, including rupture of the fibrous cap producing
myocardial infarction (MI), symptomatic transient isch-
emic attack (TIA), progressive narrowing of the femoral
artery, and restenosis after balloon angioplasty.1 Inflamma-
tion is present in the blood vessel wall well before athero-
sclerosis is visible and is associated with increased expres-
sion of endothelial cell adhesion molecules to circulating
inflammatory cells and decreased nitric oxide, collectively
termed endothelial dysfunction.2 Monocytes and neutro-
phils infiltrate into the blood vessel wall and liberate cyto-
kines and other mediators that amplify vascular inflamma-
tion. Although the inflammatory process is primarily
located in the vascular wall and surrounding tissue, the
clinical detection of inflammation in patients is made pre-
dominantly from circulating “spill over” biomarkers.
Many prospective studies have established an associa-
tion between biomarkers of inflammation and first and
recurrent cardiovascular events (CVEs). For example, stud-
ies have noted that the circulating adhesion molecules
soluble intercellular adhesion molecule-1 and soluble vas-
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http://dx.doi.org/10.1016/j.jvs.2012.08.045ular cell adhesion molecule-1 are elevated in the plasma of
atients before the development of peripheral artery disease
PAD), while deficiencies have been found in anti-
nflammatory cytokines such as high-molecular-weight and
otal adiponectin along with interleukin-10 (IL-10).3-5
he inflammatory cytokines, IL-6 and IL-1, as well as the
cute-phase proteins, C-reactive protein (CRP), fibrino-
en, and serum amyloid A, have all been associated with
AD and its progression.6,7
However, among the many inflammatory biomarkers
valuated, high-sensitivity CRP has emerged to be the
eading biomarker for clinical application. This is because
RP is a very stable analyte over time, has a relatively long
alf-life, no diurnal variation, and requires no special pre-
autions for sampling.8 The ability of CRP to predict
VEs, including PAD, has been confirmed in 20 diverse
opulation cohorts on multiple continents.3,9 Very low
0.5 mg/L) and very high (10.0 mg/L) values of CRP
oth provide important prognostic information on cardio-
ascular risk.8,10
The use of CRP has not been without controversy,
owever. Reports from the Framingham Heart Study and
he Reykjavik Heart Study have suggested that the predic-
ive ability of CRP is significantly weakened after multivari-
ble adjustment and, therefore, has limited clinical rele-
ance.11,12 Further, genetic studies examiningCRP-related
enotypes as proxies for lifelong CRP concentration failed
o demonstrate an association between genotype and risk of
oronary heart disease.13 Despite these controversies, the
enters for Disease Control and Prevention presented the
rst guidelines for the CRP tests as an adjunct to global risk
rediction.14
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December 20121800 OwensSeveral large prospective clinical trials have provided
unequivocal evidence that 3-hydroxy-3-methyl-glutaryl-
coenzyme A (HMG-CoA) reductase inhibitors (statins)
reduce cardiovascular mortality and nonfatal CVEs in a
manner largely dependent on their ability to reduce choles-
terol.15,16 Ameta-analysis that included 90,056 individuals
in 14 randomized prospective trials demonstrated an 5%
reduction in risk per 10 mg/dL reduction in low-density
lipoprotein cholesterol (LDL-C) during a mean of 5 years
of treatment.17 Statins also reduce inflammation in a dose-
dependent manner largely independent of cholesterol-
lowering effects and are themost studied anti-inflammatory
agents.18,19
The cellular and molecular mechanisms by which statins
exert their anti-inflammatory effects have been extensively
reviewed.20 Among them include improvement in endo-
thelial function, decreased endothelial cell adhesion mole-
cule expression and recruitment of inflammatory cells into
the vascular wall, and decreased smooth muscle cell prolif-
eration. Many of the pleiotropic effects are rapidly reversed
upon statin withdrawal, and withholding statin treatment
during acute ischemic events is not recommended.21 Cur-
rently novel anti-inflammatory molecules that do not affect
lipid levels are in clinical investigation and will formally test
the hypothesis that decreasing inflammation per se will
improve cardiovascular outcomes. This evidence summary
highlights the important milestones in the quest of proving
causality between inflammation and clinical events.
METHODS
Studies were identified by searching the MEDLINE
database for all published reports evaluating the effective-
ness of statins and other anti-inflammatory agents for re-
ducing cardiovascular events. Because statins potently re-
duce lipid levels (an established causative risk factor in
coronary disease), selected studies were limited to those
designed to explicitly explore the inflammatory hypothesis
in primary or secondary prevention. Lifestyle modifica-
tions, such as weight loss, exercise, nutritional supplemen-
tation, and smoking cessation, although extremely important
adjuncts to reduce inflammation, are not included due to
the limited scope of this report.
RESULTS
Seven statin trials and four anti-inflammatory trials with
novel agents were identified (Table 1).19,22-27 Analysis of
two randomized trials suggests the magnitude of risk re-
duction attributable to statin therapy is greatest in the
presence of inflammation. In the Cholesterol and Recur-
rent Events (CARE) trial of secondary prevention, the
magnitude of benefit associated with pravastatin use was
nearly 55% for those with elevated CRP levels vs only 25%
for those with low CRP levels.22 Similarly, a post hoc
analysis of the Air Force/Texas Coronary Artery Preven-
tion (AFCAPS/TexCAPS) study, in which baseline CRP
was measured in 5742 apparently healthy men and women
with average cholesterol levels, showed lovastatin was
highly effective in reducing cardiovascular events in patients Tith low LDL-C levels but high levels of inflammation.23
ogether, these data implicate inflammation in cardiovas-
ular events and suggest that statin therapy may have effi-
acy in the presence of systemic inflammation, even in the
bsence of overt hyperlipidemia.
Of particular relevance to vascular surgeons were the
esults of the Aggrastat-to-Zocor (A to Z) study.26 In this
tudy, CRP was measured 30 days after MI in patients
llocated to intensive treatment with simvastatin (40 mg/d
or the first 30 days then 80 mg/d) or to a delayed
onservative treatment with placebo (4 months) and then
reatment with simvastatin (20 mg/d). As expected, pa-
ients randomized to the intensive simvastatin regimen had
ower CRP levels at 30 days than those who received the
lacebo; however, levels of CRP achieved at 30 days pre-
icted mortality at 2 years.
Collaborating evidence for improved outcomes with
on treatment” reduced CRP levels comes from the Prav-
statin or Atorvastatin Evaluation and Infection Therapy—
hrombolysis in Myocardial Infarction 22 (PROVE IT
IMI 22) trial and the Reversal of Atherosclerosis With
ggressive Lipid Lowering (REVERSAL) trials.19,25 Col-
ectively, these data suggest that aggressive reduction of
nflammation with intensive statin therapy after a vascular
vent or vascular surgery may improve outcomes. Whether
his would hold true after a peripheral ischemic event (or
fter peripheral vascular surgery) has not been formally
ested.
The JUPITER (Justification for the Use of statins
n Primary prevention: an Intervention Trial Evaluat-
ng Rosuvastatin) trial. The primary objective of the
UPITER trial was to determine whether treatment with
osuvastatin would reduce the rate of first major CVE in
atients with normal cholesterol levels but high levels of
nflammation.27 The inclusion criteria of the trial stipulated
hat patients have a mean high-sensitivity CRP2.0 mg/L
median, 4.2 mg/L) and LDL-C levels 130 mg/dL
median, 108 mg/L). The trial was terminated early be-
ause rosuvastatin resulted in a 44% reduction in the com-
osite primary end point of MI, stroke, hospitalization for
nstable angina, arterial revascularization, and cardiovascu-
ar death. Of particular interest to the surgical community
as the 46% reduction in arterial revascularization and 48%
eduction in stroke in patients allocated to rosu-
astatin. The latter is particularly intriguing given the favor-
ble data of statins in patients with carotid stenosis.28-30
or example, in the Stroke Prevention by Aggressive Re-
uction in Cholesterol Levels (SPARCL) Trial, patients
andomized to 80 mg of atorvastatin after stroke or TIA
nd who had no known coronary disease exhibited a reduc-
ion in nonfatal and fatal stroke and a reduction in subse-
uent TIAs.29
Thus, JUPITER determined that individuals with ele-
ated levels of inflammatory biomarkers are at high vascular
isk, even when other risk factors are acceptable. And,
ndividuals at increased risk due to inflammation benefit
rom therapy they otherwise would not have received.
hese data from JUPITER resulted in a change by the U.S.
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Volume 56, Number 6 Owens 1801Food and Drug Administration label for rosuvastatin in
primary prevention of men and women with a CRP 2.0
mg/L and one additional risk factor.
Beyond JUPITER. Although the results of the
above-mentioned statin trials are provocative, it remains
unknown whether inhibition of inflammation will lower
vascular risk in patients with persistent inflammation de-
spite the use of usual cardiovascular medications. Certain
Table I. Key statin trials providing clinical evidence that re
Study
Publication
year No. Prevention
Cholesterol and Recurrent
Events (CARE)
1998 782 Secondary
Air Force/Texas Coronary
Artery Prevention Study
(AFCAPS/TexCAPS)
2001 5742 Primary
Reversal of Atherosclerosis
With Aggressive Lipid
Lowering (REVERSAL)
2004 502 Secondary
Reversal of Atherosclerosis
With Aggressive Lipid
Lowering (REVERSAL)
2005 502 Secondary
Pravastatin or Atorvastatin
Evaluation and
Infection Therapy
Thrombolysis in
Myocardial Infarction
22 (PROVE IT TIMI
22)
2005 3745 Secondary
Aggrastat-to-Zocor trial
(A to Z)
2006 3813 Secondary
Justification for the Use of
Statins in Prevention: an
Intervention Trial
Evaluating Rosuvastatin
(JUPITER)
2008 17,802 Primary
ACS, Acute coronary syndrome; CAD, coronary artery disease; CRP, C-r
protein; IVUS, intravascular ultrasound; LDL-C, low-density lipoprotein-
infarction; RCT, randomized controlled trial.established systemic anti-inflammatory therapies, such as Porticosteroids and nonsteroidal anti-inflammatory drugs
NSAIDS), do not appear effective in reducing cardiovas-
ular events. Corticosteroids result in increased blood pres-
ure, dyslipidemia, and hyperglycemia, whereas NSAIDS,
articularly cyclooxygenase 2 selective inhibitors, reduce
rostacyclin I2, a known vasodilator and platelet inhibi-
or. Nutritional approaches to inflammation reduction,
ncluding 25-hydroxyvitamin D supplementation and
tion in inflammation improves cardiovascular events
Study design Major findings
d case-control examination
nflammatory biomarkers in
ients randomized to
vastatin vs placebo after
.
First trial demonstrating that effect
of statins is partially dependent
on the level of inflammation
present at the time of
randomization.
oc analysis of CRP levels
aseline and 1 year after
cation to lovastatin vs
cebo in primary prevention.
Lovastatin was highly effective in
reducing first CVE in patients
with elevated CRP but no
hyperlipidemia. Proved
hypothesis-generating for the
JUPITER design.
performed at baseline and
8 months in patients with
umented stable CAD in
ients randomized to
derate (40 mg pravastatin)
ntensive (80 mg
rvastatin) treatment.
Greater reduction in CRP with
intensive (36.4%) vs moderate
treatment (5.2%). IVUS
documented progression of
plaque volume (2.7%) on
moderate vs reduction in plaque
volume (0.4%) intensive
treatment.
oc analysis of the
VERSAL trial to determine
relationship between
L-C and CRP and the rate
rogression of
erosclerosis.
There was a weak correlation
between CRP and LDL-C
lowering with statin.
Independent correlation
between CRP reduction and the
rate of plaque regression after
adjusting for lipids.
omized 2  2 factorial
ign of intensive
rvastatin 80 mg) vs
derate (pravastatin 40 mg)
in therapy after ACS.
Best outcomes achieved with
LDL-C 70 mg/dL and CRP
levels 2 mg/L. Suggested dual
target. Suggested incremental
value in CV risk reduction to
lowering hsCRP 2 mg/L
regardless of LDL-C levels.
early intensive statin vs
ayed conservative statin
tment in patients with
TEMI. Post-
domization analysis.
Early intensive statin treatment
reduced 30-day CRP after MI.
Patients with elevated hsCRP at
30 days had worse outcomes vs
those with values of 1.0 mg/
L.
Rosuvastatin (n 8901) vs
ebo (n 8901) in patients
h LDL-C130 mg/dL and
P2.0 mg/L.
Prospectively confirmed results of
post hoc analysis of AFCAPS/
TexCAPS. Overall, 44%
reduction of first CVE in
patients randomized to
rosuvastatin, including MI,
stroke, or death. Each individual
end point was reduced,
including a 46% reduction in
arterial revascularization.
e protein; CVE, cardiovascular events; hsCRP, high-sensitivity C-reactive
terol; MI, myocardial infarction; NSTEMI, non-ST elevation myocardialduc
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PADMA 28, a Tibetan herbal mixture with anti-inflammatory
properties, has been used for 50 years in Europe and is
approved by the Swiss Agency for Therapeutic Products for
patients with Fontaine stage II peripheral occlusive dis-
ease.32
However, several pertinent novel anti-inflammatory
agents are currently being tested in clinical trials (Table
II).33-37 The Canakinumab Anti-inflammatory Thrombo-
sis Outcomes Study (CANTOS) will directly test the in-
flammatory hypothesis in a secondary prevention setting by
using monoclonal anti–IL-1 antibody for the secondary
prevention of cardiovascular disease and new-onset diabe-
tes.36 IL-1 has been implicated in the initiation and ampli-
fication of the local (IL-1	) and systemic inflammatory
(IL-1) response. This cytokine-based therapy aims to
truncate the inflammatory cascade.
Taking another approach, the MRC-ILA-HEART
(Medical Research Council Investigation of the effect of
Table II. Anti-inflammatory agents in clinical trials to red
Study
Publication
year No. Preve
Aggressive Reduction of
Inflammation Stops Events
(ARISE)
2008 6144 Seco
Integrated Biomarker and
Imaging Study 2
2008 330 Seco
The MRC-ILA-HEARTS Study Ongoing 186 Seco
Cardiovascular Inflammation
Reduction Trial (CIRT)
Ongoing 7000 Seco
Canakinumab Anti-inflammatory
Thrombosis Outcomes Study
(CANTOS)
Ongoing 17,200 Seco
ACS, Acute coronary syndrome; CAD, coronary artery disease; CRP, C
high-density lipoprotein-cholesterol; IL, interleukin; IL-1Ra, interleukin I
lipoprotein-associated phospholipase A2; MI, myocardial infarction; MRC-I
kin-1 receptor Antagonist on markers of inflammation in non-ST elevatio
myocardial infarction; RA, rheumatoid arthritis; RCT, randomized control
aLp-PLA2 is associated with rupture-prone plaque.Interleukin-1 receptor Antagonist on markers of inflamma- gion in non-ST elevation acute coronary syndromes) study
ill take advantage of the specific IL-1 receptor antagonist,
he only known naturally occurring cytokine antagonist, to
brogate inflammation.37
Other broadly acting anti-inflammatory agents, such as
ethotrexate, have been shown to lower the inflammatory
iomarkers, CRP, IL-6, and tumor necrosis factor-	, and
educe cardiovascular mortality in patients with rheuma-
oid arthritis.38 The cardiovascular inflammation reduction
rial will randomize patients with established coronary ar-
ery disease (CAD) and CRP 2 mg/L, despite adequate
edication including statin, to low-dose methotrexate (10
g/wk) or placebo. The end point will be MI, stroke, or
ardiovascular death.35 The results of these trials will pro-
uce important biologic insights into the association of
nflammation and CVE.
Patients with PAD. Patients with PAD have worse
ardiovascular outcomes and higher mortality than do pa-
ients with CAD alone.39,40 One explanation is that, in
ardiovascular risk
Study design Major findings
RCT of the anti-inflammatory/
antioxidant succinobucol vs
placebo after ACS.
No difference in composite
primary end point of CV
death, cardiac arrest, MI,
stroke, UA, or coronary
revascularization. No
significant change in
CRP. Succinobucol
increased LDL-C and
SBP, and decreased
HDL-C.
Darapladib (direct Lp-PLA2
a
inhibitor) vs placebo. IVUS
end point.
Darapladib reduced IVUS-
detected coronary
atherosclerotic plaque
necrotic core volume.
RCT phase II trial of IL-1Ra vs
placebo in patients after
NSTEMI ACS.
Trial will assess whether
treatment of NSTEMI
ACS with IL-1Ra alters
the inflammatory
response.
RCT in patients with stable MI
to MTX (10 mg/wk) vs
placebo.
Low-dose MTX lowers
CRP and IL-6 in
patients with RA with no
effects of platelet
function or cholesterol.
MTX in RA appears to
reduce CV risk.
RCT in patients with stable
CAD and CRP 2 mg/L to
receive canakinumab vs
placebo to reduce composite
end point of MI, stroke, or
CV death.
Canakinumab is a human
monoclonal antibody
that selectively
neutralizes the
inflammatory cytokine
IL-1.
ve protein; CV, cardiovascular; IVUS, intravascular ultrasound; HDL-C,
ceptor antagonist; LDL-C, low-density lipoprotein-cholesterol; Lp-PLA2,
EARTS, Medical Research Council Investigation of the effect of Interleu-
te coronary syndromes; MTX, methotrexate; NSTEMI, non-ST elevated
l; SBP, systolic blood pressure; UA, unstable angina.uce c
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Volume 56, Number 6 Owens 1803inflammation than typically seen in patients with CAD
alone. One prospective cohort study determined that the
mean value of CRP was 12.0 mg/L (median, 3.0 mg/L) in
a cohort of PAD patients undergoing lower extremity vein
bypass surgery, a value that placed them at high inflamma-
tory risk.41 In this population, inflammation was an inde-
pendent predictor of 2- to 5-year all-cause mortality, even
after controlling for lipid levels and other risk factors (Fig
1).42-45 Indeed, most of these patients had CRP levels 2
mg/L and LDL-C 130 mg/dL, precisely the cohort
tested in the JUPITER trial.42 A substantial minority of
these patients had extreme inflammation, with values as
high as 50 or 100 mg/L.
Patients with the highest level of inflammation often
have a perturbed biochemistry characterized by moderate
renal impairment and hypoalbuminemia, each significantly
and independently contributing to mortality (Fig 2). Al-
though statin therapy has been shown to only be of modest
benefit in certain high-risk populations, such as those on
Area under ROC curve = .7059
Clinical Model = Age, DM, CAD, CLI
0.
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0.
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0.
50
0.
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1.
00
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n
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1 - Specificity
Area under ROC curve = .7739
Clinical model + eGFR + Albumin (tertile)
0.
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1 - Specificity
Fig 1. The receiver operating characteristic curves (ROC)
undergoing lower extremity bypass surgery. A, A clinical m
diabetes mellitus (DM), extant coronary disease (CAD), a
added to the clinicalmodel were (B) renal function, as defin
albumin, and (D) e-GFR, albumin, and high-sensitivity C-r
the accuracy of the model as evidenced by the increasing a
variables, has an 82% accuracy of predicting midterm mortahemodialysis, no study to date has examined the effective- hess of statins on PAD patients with high levels of inflam-
ation, renal insufficiency, and malnutrition.46,47 In fact,
o anti-inflammation trials have been conducted to deter-
ine if it is possible to mitigate the high mortality in this
ruly vulnerable population.
ISCUSSION
Fifteen years ago, the Physician’s Health Study re-
orted that in apparently healthy men, plasma CRP con-
entrations preceded the onset of cardiovascular events and
hat the effectiveness of aspirin therapy was most robust
mong those in the highest tertile,48 hence providing clin-
cal evidence that atherosclerosis was in part an inflamma-
ory disorder. Since then, multiple lifestyle and pharmaco-
ogic therapies that reduce cardiovascular risk, including
moking cessation, exercise, weight reduction, and statins,
lso lower CRP. Conversely, drug therapies that do not
ffect inflammation, including succinobucol, ezetimibe,
orcetrapib, and hormone replacement therapy (HRT),
Area under ROC curve = .7272
Clinical model  + eGFR
0.
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Area under ROC curve = .8127
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area under the ROC curves are presented for 225 patients
for prediction of midterm mortality was created with age,
e presence of critical limb ischemia (CLI). Subsequently
estimated glomerular filtration rate (eGFR), (C) eGFR and
e protein (hsCRP). Each biochemical parameter improved
der the curve value. The final model, consisting of seven
dapted from Owens et al.42Se
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December 20121804 Owensrisk.33,49-51 Indeed, HRT, known to increase CRP levels,
was shown to increase cardiovascular risk.51,52 Anticyto-
kine therapy is promising; however, there is much redun-
dancy, such that neutralization of one cytokine may be
insufficient to halt the inflammatory cascade. To date, no
large-scale clinical trial has yet established that an anti-
inflammatory intervention that does not alter lipid levels
can improve cardiovascular outcomes, and therefore, the
clinical evidence remains circumstantial.
Has inflammation, as currently measured by CRP, se-
cured its place among traditional vascular risk factors, such
as lipids, in the secondary prevention of CVE? It certainly
appears so in predicting 2-year to 5-year mortality.42 How-
ever, the utility of CRP as a predictivemarker or therapeutic
target is understudied in the PAD population and it is not
without controversy. The concept of dual targets (LDL-C
70 mg/dL and high-sensitivity CRP 2.0 mg/L) is
supported by several large randomized controlled trials,
such as PROVE-IT, A to Z, and REVERSAL, indicating
that achieving both goals is equally important.19,25,26
Therefore, treatment strategy would be aimed not only at
reducing LDL-C but also at reducing inflammation. Un-
fortunately, those trials were conducted for patients with
CAD, and relatively little attention has been paid to the
intensity of statin therapy and the desired targets in patients
with PAD.53 Atorvastatin (80 mg) and rosuvastatin (40
mg) are the most effective statins in reducing LDL-C and
CRP and could be used to achieve dual targets in patients
Inflammation (hsC
Malnutrition (albumin < 3.5mg/dL)
%72
37%
17%
9%
15%
HR=6.7
HR=4.54
HR=3.77
HR=9.08
HR=5.65
Fig 2. Venn diagram of 225 patients undergoing perip
considerable overlap among subsets of patients with m
synergism of different mechanisms for the hazard of death
glomerular filtration (eGFR) 60 mL/min/1.73 m2, 6
high-sensitivity C-reactive protein (hsCRP)5.0 mg/L.
three circles have a hazard ratio for death of 9.08. Adaptwith the highest levels of inflammation.54As an alternative to the use of CRP alone, it is also
ossible that an inflammation panel could be developed
hereby both proinflammatory and anti-inflammatory
ompounds would be measured simultaneously so that the
et inflammatory balance could be calculated. There is
xperimental evidence that atherosclerosis may result from
relative deficiency of endogenous anti-inflammatory or
ro-resolving compounds, but this has not been prospec-
ively tested.55
ONCLUSIONS
The statin trials have taught us that identifying patients
t high inflammatory risk despite conventional treatment,
ncluding statin therapy, remain vulnerable for increased
VE. But statin trials have taken us as far as they can in
roving causality between inflammation and vascular out-
omes and we must await the results of the second
eneration of inflammation trials. Indeed, an anti-inflammatory
lternative to statin therapy is desirable given the recent
ata showing that some statins slightly increase the risk of
iabetes mellitus and cognitive impairment.56
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